# A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer

> **NCT00411788** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 11 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Rapamycin
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT00411788
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2016-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00411788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00411788, "A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00411788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*